Cantargia has carried out a private placement of shares of approximately SEK 564 million at a subscription price of SEK 62 per share. The subscription price was determined through an accelerated bookbuilding procedure.
Cantargia is a biotechnology company that develops antibody-based treatments for life-threatening diseases. The basis for this is the protein IL1RAP that is involved in a number of diseases and where Cantargia has established a platform. The main project, the antibody CAN04, is being studied clinically as combination therapy with chemotherapy or immune therapy with a primary focus on non-small cell lung cancer and pancreatic cancer. Cantargia’s second project, the antibody CAN10, addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on systemic sclerosis and myocarditis.
Carnegie Investment Bank, Kempen & Co and Oppenheimer & Co. acted as Joint Bookrunners. Baker McKenzie acted as legal advisor to the Joint Bookrunners, with a capital markets team from Stockholm consisting of Joakim Falkner, Johanna Flink and Ian Gulam, as well as Adam Farlow from the Firm's capital markets group in London and Paul DePasquale from the tax group in New York.